- Home
- ITCI
as 10-22-2024 4:00pm EST
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 8.0B | IPO Year: | N/A |
| Target Price: | $97.00 | AVG Volume (30 days): | 438.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.86 | EPS Growth: | N/A |
| 52 Week Low/High: | $45.50 - $84.89 | Next Earning Date: | 10-30-2024 |
| Revenue: | $564,526,000 | Revenue Growth: | 54.31% |
| Revenue Growth (this year): | 46.6% | Revenue Growth (next year): | 37.06% |
Stock Insider Trading Activity of Intra-Cellular Therapies Inc. (ITCI)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Mates Sharon | ITCI | Chairman and CEO | Aug 29 '24 | Sell | $72.94 | 70,000 | $5,089,235.50 | 1,076,101 | |
| Mates Sharon | ITCI | Chairman and CEO | Aug 26 '24 | Sell | $73.66 | 95,925 | $7,054,085.49 | 1,076,101 |
Latest Intra-Cellular Therapies Inc. News
ITCI Breaking Stock News: Dive into ITCI Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast
Insider Monkey
9 days ago
Intra-Cellular Therapies, Inc. (ITCI): Among the Most Promising Mid-Cap Stocks According to Hedge Funds
Zacks
12 days ago
Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe
MT Newswires
12 days ago
Morgan Stanley Raises Price Target on Intra-Cellular Therapies to $95 From $92, Keeps Overweight Rating
GuruFocus.com
13 days ago
JPMorgan Chase & Co's Strategic Acquisition of Shares in Intra-Cellular Therapies Inc
MT Newswires
19 days ago
RBC Lifts Price Target on Intra-Cellular Therapies to $108 From $106, Keeps Outperform Rating
GlobeNewswire
a month ago
Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress
Simply Wall St.
a month ago
Intra-Cellular Therapies (NASDAQ:ITCI) delivers shareholders fantastic 54% CAGR over 5 years, surging 3.9% in the last week alone
Compare ITCI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ITCI Intra-Cellular Therapies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.